Long Non-Coding RNA MCM3AP-AS1: A Crucial Role in Human Malignancies.
MCM3AP-AS1
biomarker
cancer
clinical features
lncRNA
Journal
Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2021
accepted:
31
05
2022
entrez:
5
7
2022
pubmed:
6
7
2022
medline:
7
7
2022
Statut:
epublish
Résumé
The incidence of cancer continues to grow and is one of the leading causes of death in the world. Long noncoding RNAs (LncRNAs) is a group of RNA transcripts greater than 200 nucleotides in length, and although it cannot encode proteins, it can regulate different biological functions by controlling gene expression, transcription factors, etc. LncRNA micro-chromosome maintenance protein 3-associated protein antisense RNA 1 (MCM3AP-AS1) is involved in RNA processing and cell cycle-related functions, and MCM3AP-AS1 is dysregulated in expression in various types of cancers. This biomarker is involved in many processes related to carcinogens, such as cell proliferation, apoptosis, cell cycle, and migration. In this review, we summarize the roles of MCM3AP-AS1 in different human cancers and its biological functions with a view to providing ideas for future research.
Identifiants
pubmed: 35783356
doi: 10.3389/pore.2022.1610194
pii: 1610194
pmc: PMC9243217
doi:
Substances chimiques
Intracellular Signaling Peptides and Proteins
0
RNA, Antisense
0
RNA, Long Noncoding
0
Acetyltransferases
EC 2.3.1.-
MCM3AP protein, human
EC 2.3.1.-
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610194Informations de copyright
Copyright © 2022 Ma, Wu, Wu, Fa and Chen.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
BMC Musculoskelet Disord. 2019 Dec 13;20(1):605
pubmed: 31836002
Lancet. 2019 Oct 19;394(10207):1467-1480
pubmed: 31631858
Oncol Res. 2016;23(5):205-17
pubmed: 27098144
Mol Syndromol. 2021 Oct;12(6):372-378
pubmed: 34899146
Clin Chim Acta. 2020 Apr;503:1-18
pubmed: 31901481
Lancet. 2017 Mar 18;389(10074):1134-1150
pubmed: 27865536
Cell Death Dis. 2019 Sep 30;10(10):731
pubmed: 31570691
Front Oncol. 2020 Jun 23;10:705
pubmed: 32714856
Mol Cancer. 2019 May 27;18(1):102
pubmed: 31133028
Tumour Biol. 2016 Mar;37(3):2779-88
pubmed: 26715267
J Cell Biochem. 2020 Mar;121(3):2258-2267
pubmed: 31693222
Mol Cancer. 2020 Mar 19;19(1):62
pubmed: 32192494
Nature. 2013 Sep 19;501(7467):338-45
pubmed: 24048066
Endocrine. 2019 Aug;65(2):318-326
pubmed: 31030335
Lancet. 2018 Mar 31;391(10127):1301-1314
pubmed: 29307467
Mol Ther Nucleic Acids. 2020 Jun 5;20:265-278
pubmed: 32193153
Int J Mol Sci. 2013 Dec 04;14(12):23672-84
pubmed: 24304541
Cancer Med. 2018 Mar;7(3):842-855
pubmed: 29473328
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Mol Cell Endocrinol. 2018 Jul 5;469:11-22
pubmed: 28751134
Mol Med Rep. 2020 Oct;22(4):3081-3094
pubmed: 32945445
Exp Ther Med. 2020 Aug;20(2):978-984
pubmed: 32742341
Eur Rev Med Pharmacol Sci. 2020 Mar;24(5):2452-2461
pubmed: 32196596
Pathol Res Pract. 2018 Dec;214(12):2031-2038
pubmed: 30316688
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990064
pubmed: 33596783
Cancer Manag Res. 2020 Jun 22;12:4799-4806
pubmed: 32606969
Cancer Med. 2021 Apr;10(7):2470-2481
pubmed: 33686713
Br J Biomed Sci. 2021 Apr;78(2):53-57
pubmed: 32678686
Life Sci. 2019 Aug 15;231:116335
pubmed: 30898647
Cancer Manag Res. 2020 Jul 16;12:5845-5855
pubmed: 32765087
Am J Med Sci. 2018 Aug;356(2):130-134
pubmed: 30219154
J Investig Med. 2020 Oct;68(7):1282-1288
pubmed: 32690597
J Oncol Pract. 2018 Nov;14(11):665-671
pubmed: 30423267
Mol Med. 2019 Dec 12;25(1):55
pubmed: 31830901
Oncogene. 2017 Oct 12;36(41):5661-5667
pubmed: 28604750
Oncol Lett. 2021 Mar;21(3):211
pubmed: 33510812
Expert Rev Anticancer Ther. 2019 Feb;19(2):105-119
pubmed: 30582397
Front Oncol. 2019 Nov 05;9:1156
pubmed: 31750247
Genes Dev. 2018 Sep 1;32(17-18):1105-1140
pubmed: 30181359
Crit Rev Eukaryot Gene Expr. 2021;31(4):81-87
pubmed: 34587438
DNA Cell Biol. 2019 Aug;38(8):857-864
pubmed: 31237446
Future Oncol. 2017 Feb;13(5):443-453
pubmed: 27841659
FEBS Lett. 2018 Sep;592(17):2884-2900
pubmed: 29972883
Genomics. 2002 Jun;79(6):824-32
pubmed: 12036297
J Int Med Res. 2020 Sep;48(9):300060520935215
pubmed: 32940099
Nat Rev Drug Discov. 2020 Oct;19(10):673-694
pubmed: 32782413
Lancet. 2020 Aug 29;396(10251):635-648
pubmed: 32861308
Mol Cancer. 2019 Feb 19;18(1):28
pubmed: 30782188
Future Oncol. 2017 Nov;13(27):2479-2487
pubmed: 29121780
J Cell Biochem. 2019 Aug;120(8):13487-13493
pubmed: 30916832
Front Mol Biosci. 2021 Sep 29;8:753218
pubmed: 34660700
Cancer Cell. 2016 May 9;29(5):653-668
pubmed: 27117758
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Eur J Cancer. 2016 Apr;57:10-22
pubmed: 26851397
Oncol Lett. 2021 Mar;21(3):225
pubmed: 33613714
Cancer Cell Int. 2018 Jul 28;18:107
pubmed: 30069164
Cancer Manag Res. 2020 Sep 07;12:8117-8124
pubmed: 32982409
Hum Cell. 2022 Jan;35(1):150-162
pubmed: 34822133
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Biosci Rep. 2020 Feb 28;40(2):
pubmed: 31985002
Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54
pubmed: 26883671
BMC Cancer. 2014 May 10;14:331
pubmed: 24885752
Cell Metab. 2018 Apr 3;27(4):714-739
pubmed: 29617640
Cell Death Dis. 2019 Jul 30;10(8):573
pubmed: 31363080
Oncotarget. 2016 Jul 5;7(27):41737-41747
pubmed: 27229531
Cancer Cell Int. 2020 Jul 13;20:307
pubmed: 32684844
Biomed Pharmacother. 2020 Aug;128:110289
pubmed: 32485570
Clin Chim Acta. 2020 May;504:190-200
pubmed: 31790697
Onco Targets Ther. 2020 Sep 22;13:9365-9376
pubmed: 33061424
Cells. 2019 Sep 01;8(9):
pubmed: 31480503
J Gene Med. 2021 Mar;23(3):e3306
pubmed: 33450091
Nat Rev Nephrol. 2021 Apr;17(4):245-261
pubmed: 33144689